Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jul;52(1):100-3.
doi: 10.1046/j.0306-5251.2001.01411.x.

Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes

C Senda  1 , Y Yamaura, K Kobayashi, H Fujii, H Minami, Y Sasaki, T Igarashi, K Chiba
Affiliations

Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes

C Senda et al. Br J Clin Pharmacol. 2001 Jul.

Abstract

Aims: To study the influence of CYP2D6*10 on the formation of p-hydroxymexiletine (PHM) and hydroxymethylmexiletine (HMM) using microsomes from human liver of known genotypes.

Methods: Microsomes from human livers of genotype CYP2D6*1/*1 (n = 5), *1/*10 (n = 6) and *10/*10 (n = 6) were used in this study. The formation of PHM and HMM was determined by high-performance liquid chromatography.

Results: The formation rates of PHM and HMM were decreased by more than 50% and 85% in CYP2D6*1/*10 and *10/*10 microsomes, respectively, compared with *1/*1 microsomes.

Conclusions: The metabolism of mexiletine to form PHM and HMM appears to be impaired to a significant extent in human liver microsomes from hetero- and homozygotes of CYP2D6*10.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mexiletine hydroxylation activity in microsomes from human livers genotyped as CYP2D6*1/*1 (n = 5), *1/*10 (n = 6), *10/*10 (n = 6) and *5/*5 (n = 1). (a) PHM formation and (b) HMM formation. Each bar represents the mean value and the error bar represents s.d.
See this image and copyright information in PMC

References

    1. Campbell NPS, Kelly JG, Adgey AAJ, Shanks RG. The clinical pharmacology of mexiletine. Br J Clin Pharmacol. 1978;6:103–108. - PMC - PubMed
    1. Broly F, Vandamme N, Libersa C, Lhermitte M. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. Br J Clin Pharmacol. 1991;32:459–466. - PMC - PubMed
    1. Turgeon J, Fiset C, Giguere R, et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. J Pharmacol Exp Ther. 1991;259:789–798. - PubMed
    1. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46:452–459. - PubMed
    1. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000;50:31–34. - PMC - PubMed